SHANGHAI, Sept. 7, 2025 /PRNewswire/ -- Epigenic Therapeutics ("Epigenic"), a clinical-stage innovative drug development company, today announced the completion of a $60 million Series B round of financing led by Lapam Capital, with continued participation from existing investors Qiming...
Hence then, the article about epigenic therapeutics announces completion of 60 million series b financing to accelerate clinical development of epigenetic medicines was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Epigenic Therapeutics Announces Completion of $60 Million Series B Financing to Accelerate Clinical Development of Epigenetic Medicines )
Also on site :
- Large plume of smoke visible from I-290 billows from west suburban building fire
- Legendary Rock Band's Latest Single Is 'Quite Cinematic', Says Lead Singer: Exclusive
- TCPC Deadline: TCPC Investors with Losses in Excess of $100K Have Opportunity to Lead BlackRock TCP Capital Corp. Securities Fraud Lawsuit